FMP
Interpace Biosciences, Inc.
IDXG
PNK
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
0.75 USD
0.105 (14%)
About
ceo
Dr. Thomas W. Burnell Ph.D.
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://www.interpace.comexchange
PNK
Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
CIK
0001054102
ISIN
US46062X3035
CUSIP
46062X303
Address
Morris Corporate Center 1
Phone
855 776 6419
Country
US
Employee
111
IPO Date
May 20, 1998
Key Executives
Name
Title
Pay
Year Born
Dr. Sydney D. Finkelstein M.D.
Chief Scientific Officer
0
N/A
Mr. Christopher McCarthy
Chief Financial Officer & Chief Operatin...
395.78k
1992
Dr. Nicole Massoll M.D.
Chief Medical Officer
0
N/A
Mr. Patrick Kane
Vice President & Corporate Controller
0
N/A
Dr. Thomas W. Burnell Ph.D.
President, Chief Executive Officer & Cha...
657.73k
1963
As of December 31, 2024, the total employee count stands at 111, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
